Novo Nordisk A/S : Share repurchase programme

Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 13 January 2014 - On 31 October 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January

2013.
Under the programme initiated 31 October 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 31 October 2013 to 28 January
2014.
Since the announcement as of 23 December 2013, the following transactions have been made under the programme:

Number of shares Average purchase price Transaction value, DKK Accumulated, last announcement 9,388,055 1,800,000,081

2 January 2014 265,000 200.77 53,204,792

3 January 2014 240,000 203.66 48,877,656

6 January 2014 275,000 205.08 56,396,945

7 January 2014 265,000 205.43 54,439,613

8 January 2014 265,000 207.51 54,990,044

9 January 2014 265,000 209.64 55,553,593

10 January 2014 265,000 210.20 55,702,417

Accumulated under the programme 11,228,055 2,179,165,141

With the transactions stated above, Novo Nordisk owns a total of 104,692,025 treasury shares, corresponding to 3.8% of the share capital. The total amount of shares in the company is 2,750,000,000 including treasury shares.

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

[phone]

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 2 / 2014

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 10 January 2014, Novo Nordisk has repurchased a total of 69,420,270 B shares equal to a transaction value of DKK
13,366,985,811.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B

shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information Media: Anne Margrethe Hauge Ken Inchausti (US)	[phone] [phone]	[e-mail] [e-mail]
Investors: Kasper Roseeuw Poulsen	[phone]	[e-mail]
Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen Jannick Lindegaard (US)	[phone] [phone] [phone] [phone]	[e-mail] [e-mail] [e-mail] [e-mail]

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

[phone]

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 2 / 2014